Ipsen reported US$88M of Iqirvo® net sales in PBC for 4Q25, bringing 2025 sales to US$208M, triggering the first commercial milestone payment to GENFIT ahead of schedule1Ipsen confirmed its commitment to launch a Phase 3 in PSC, creating a new avenue for potential future upside for GENFITGENFIT’s CCA Phase 1b study progressing as planned: New dose-escalation cohort fully enrolled with no dose-limiting toxicities reported at the 21-day timepoint Phase 1b data readout and recommended Phase 2 doses remain on t ...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 350 points on Thursday.The Dow traded down 1.21% to 49,515.62 while the NASDAQ fell 1.55% to 22,709.08. The S&P 500 also fell, dropping, 1.18% to 6,859.69.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsUtilities shares gained by 2.4% on Thursday.In trading on Thursday, information technology stocks fell by 1.5%.Top HeadlineAmerican Electric Power Comp ...

LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises PomDoctor Ltd., (“PomDoctor” or the "Company") (NASDAQ: POM) investors of a class action on behalf of investors that bought securities between October 9, 2025 and December 11, 2025, inclusive (the “Class Period”). PomDoctor investors have until April 6, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal ri ...

AI-driven market disruption could hit loans and high-yield credit, UBS says Proactive uses images sourced from Shutterstock The recent selloff in credit markets reflects growing concern that artificial intelligence (AI) is moving faster than many expect, and its impact may extend well beyond software, according to UBS analysts. In a note to clients, the bank’s analysts said markets have only partially priced in the risk, particularly for lower-quality credit sectors in the US. Investment-grade (IG) bonds ...

文/李后强 中共四川省委四川省人民政府决策咨询委员会副主任、成都市社会科学界联合会主席、四川省社会科学院教授、博士生导师 春节作为中华民族最重要的传统节日，正焕发出新的经济活力。2026年春节，全社会跨区域人员流动量预计达到95亿人次，创下历史新高。在商务部等9 单位印发《2026"乐购新春"春节特别活动方案》的推动下，各地通过发放消费券、开展以旧换新、打造新消费场景等举措，激发内需潜力。 春节消费市场已从传统的囤货购物，扩展至文旅、数字、绿色等多元消费领域，形成一股强劲的消费"暖流"。春节经济不再是简单的年货采购，而成为观 察中国消费市场韧性与活力的重要窗口。 02 业态创新，丰富消费场景 春节消费场景不断创新，从线下到线上，从传统到现代，呈现多元化趋势。线上线下融合成为新常态，2026年全国网上年货节于1月19日至3月4日举行， 围绕弘扬传统文化、丰富品质供给等主题，推出一系列特色活动。老字号企业在创新中传承。全聚德集团推出30余款产品，新品占比达50%，涵盖家宴、 白酒、熟食等品类。全聚德集团负责人表示，他们通过"年轻化战略"，在场景、产品、渠道与内容上持续创新，展现老字号在新时代的生命力。文旅融合 成 ...

在2025年11月的业绩会议中，思佳讯宣布与Qorvo的合并计划，旨在增强公司规模、技术组合和业务多 元化，以减少客户集中风险。这一战略行动的后续进展，如监管审批或整合细节，值得投资者关注。 此外，思佳讯在2026年1月9日股价出现小幅下跌，成交额减少，反映出短期市场情绪波动。公司业务持 续聚焦移动射频和广泛市场领域，如Wi-Fi7和汽车电子，这些领域的动态可能影响长期走势。 以上内容基于公开资料整理，不构成投资建议。 经济观察网思佳讯(SWKS.US)在2026年初的值得关注事件主要围绕其财务业绩和战略合并进展。 业绩经营情况 根据2025年11月的业绩电话会议，思佳讯管理层对2026财年第一季度给出了业绩展望，包括营收预期区 间为9.75亿至10.25亿美元，每股收益预期为1.40美元。移动业务预计环比下降中低个位数，而广泛市场 业务(如汽车、Wi-Fi7和数据中心)可能保持增长。季度财报发布通常是市场关注焦点，但具体发布日期 未在资料中明确。 战略推进 ...

Aftermath Silver CEO Ralph Rushton joined Steve Darling from Proactive to announce the commencement of a Pre-Feasibility Study (PFS) for the company’s Berenguela silver-copper-manganese project in southern Peru, marking a significant milestone as the company advances the asset toward a potential production decision. Rushton told Proactive that the move to initiate a PFS follows the successful completion of a C$20 million equity financing and an extensive 82-hole infill drilling program carried out in 2025. ...

LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises China Liberal Education Holdings Limited, (“China Liberal” or the "Company") (OTCMKTS: CLEUF) investors of a class action on behalf of investors that bought securities between January 22, 2025 and January 30, 2025, inclusive (the “Class Period”). China Liberal investors have until March 31, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@por ...

Summary of Phathom Pharmaceuticals Conference Call Company Overview - **Company**: Phathom Pharmaceuticals (NasdaqGS:PHAT) - **Product**: VOQUEZNA, the first PCAB (Potassium-Competitive Acid Blocker) in the U.S. for gastroesophageal reflux disease (GERD) treatment - **Market Size**: 65 million patients in the U.S. suffer from gastroesophageal reflux, with a historical PPI market exceeding $10 billion in revenue [2][3][9] Core Insights - **Market Opportunity**: 40% of GERD patients on standard therapy (PPIs) are still in pain, representing a significant opportunity for VOQUEZNA to convert these patients to a more effective treatment [3][4] - **Sales Growth**: - 2024 revenue: $55 million - 2025 revenue: Estimated $175 million, indicating a growth of $120 million year-over-year [9] - Expected transition to operating profitability in the second half of 2026 [10] - **Sales Strategy Shift**: Focus has shifted from primary care to gastroenterologists, who are identified as early adopters and the primary prescribers for patients in pain [10][11][14] Financial Performance - **Revenue Growth**: Consistent growth observed each quarter in 2025 despite sales force transitions and territory realignments [27][31] - **Sales Force Realignment**: - Target lists were updated to focus on gastroenterologists, removing unproductive primary care targets [20][22] - Full-strength sales organization expected by March 2026, with approximately 300 sales reps [22] Market Penetration Goals - **PPI Market Penetration**: Current penetration at 3% of the PPI script volume within gastroenterology, with a goal to convert 20%-30% of the 20 million PPI prescriptions written by gastroenterologists, potentially leading to $1 billion in revenue [78][84] Future Outlook - **2026 Strategy**: Focus on executing the current strategy without major shifts, emphasizing sales execution and customer engagement [41][42] - **EoE Market Potential**: Ongoing trials for eosinophilic esophagitis (EoE) could extend exclusivity and provide additional revenue opportunities [96][108] - **Pipeline Development**: Plans to explore additional products for launch through existing gastroenterology relationships, focusing on assets with clear human efficacy data [123][126] Additional Considerations - **Debt Management**: Recent capital raise aimed at improving the balance sheet and renegotiating debt terms to alleviate investor concerns [73] - **Seasonal Fluctuations**: January script declines attributed to seasonal factors and insurance plan resets, not indicative of underlying demand [46][50] This summary encapsulates the key points discussed during the conference call, highlighting Phathom Pharmaceuticals' strategic focus, financial performance, and future growth opportunities in the gastroenterology market.

GFL Environmental Inc (NYSE:GFL) reported upbeat earnings for the fourth quarter on Wednesday.The company posted quarterly earnings of 26 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $1.209 billion which beat the analyst consensus estimate of $1.190 billion.GFL Environmental said it sees FY2026 sales of $7.000 billion to $7.140 billion, versus estimates of $7.070 billion.“Our more than 15,000 employees delivered another year of resu ...